智通财经网·2026-02-09 22:28Core Viewpoint - The company is advancing its self-developed innovative drug TQB2102, a HER2 dual-targeted antibody-drug conjugate (ADC), through a Phase III clinical trial to evaluate its efficacy and safety in patients with HER2 low-expressing recurrent or metastatic breast cancer [1][2] Group 1: Clinical Trial and Drug Development - TQB2102 is undergoing a randomized, open-label, parallel-controlled Phase III clinical trial (TQB2102-III-01) to compare its effectiveness against chemotherapy in HER2 low-expressing breast cancer [1] - The drug incorporates three core technological innovations: dual-target design, cleavable linker, and optimized drug-antibody ratio (DAR), enhancing its antitumor activity and safety profile [1] Group 2: Clinical Results - At the 2025 ASCO annual meeting, the company reported promising results from a Phase Ib clinical study of TQB2102 in HER2 low-expressing advanced breast cancer, showing an overall objective response rate (ORR) of 53.4% among previously treated patients [2] - Notably, in the 7.5 mg/kg group, the ORR reached 58.3%, and 44.4% of patients who had previously progressed on ADC treatment achieved a response after TQB2102 therapy [2] - The safety profile indicated that grade 3 or higher treatment-related adverse events (TRAEs) included neutropenia (23.3%), leukopenia (20.6%), anemia (8.2%), and hypokalemia (6.9%), with overall tolerability being good [2] Group 3: Market Positioning - The company has established a comprehensive portfolio in breast cancer treatment, covering various molecular subtypes including HER2+, HER2 low-expressing, HR+/HER2-, and triple-negative breast cancer, aiming to provide new treatment options across all stages of disease management [2]